PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
PTC Therapeutics (PTCT) Misses Q3 EPS by 30c, Revenues Miss
October 29, 2019 4:54 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.30 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $71.42 million versus the consensus estimate of $73.02 million.
Third Quarter 2019 Financial Highlights:
Total revenues were $71.4 million for the third quarter of 2019, compared to $53.6 million for the third quarter of 2018.Translarna net product revenues were $48.3 million for the third quarter of 2019, compared to $30.4 million for the third quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza® net product revenues were $22.9 million for the third quarter of 2019, compared to... More